Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1007/s40121-020-00349-8 http://scihub22266oqcxt.onion/10.1007/s40121-020-00349-8 33051827!7553378!33051827     free     free     free Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Infect+Dis+Ther 2020 ; 9 (4): 715-720 Nephropedia Template TP {{tp|p=33051827|t=2020. Early Treatment of COVID-19 Disease: A Missed Opportunity |pdf=|usr=}}{{33051827}} gab.com Text Early Treatment of COVID-19 Disease: A Missed Opportunity JO: Infect Dis Ther http://www.kidney.de/pget.php?&tw=1&pmid=33051827 #FOAvip Antivirals have demonstrated efficacy in treating other infectious diseases in early stages of disease, reducing morbidity, mortality, and the likelihood of onward transmission. At the time of writing, more than 1900 clinical trials are registered globally to assess the efficacy and safety of candidate therapeutics for COVID-19. The majority of these trials are designed to evaluate the comparative efficacy and safety of candidate therapeutics for the treatment of COVID-19 to prevent death among populations of hospitalized patients with advanced disease. Yet, emerging epidemiological evidence now indicates that the majority of those infected with the SARS-CoV-2, while still infectious, experience minimal or mild disease symptomology. Like HIV and hepatitis C that pioneered treatment as prevention, there is a missed opportunity for trials of early pharmaceutical intervention for COVID-19 disease evaluating not only reductions in morbidity and mortality but also transmissibility. We discuss this clinical research gap within an historical context of viral treatment as prevention for HIV and hepatitis C, and comment on the challenges and opportunities for clinical research of candidate therapeutics for early COVID-19 disease. Twit Text FOAVip Early Treatment of COVID-19 Disease: A Missed Opportunity ????Infect Dis Ther http://www.kidney.de/pget.php?&tw=1&pmid=33051827 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33051827 #FOAvip English Wikipedia <ref>{{Cite pmid|33051827}}</ref> Early Treatment of COVID-19 Disease: A Missed Opportunity #MMPMID33051827 Forrest JI; Rayner CR; Park JJH; Mills EJ Infect Dis Ther 2020[Dec]; 9 (4): 715-720 PMID33051827show ga Antivirals have demonstrated efficacy in treating other infectious diseases in early stages of disease, reducing morbidity, mortality, and the likelihood of onward transmission. At the time of writing, more than 1900 clinical trials are registered globally to assess the efficacy and safety of candidate therapeutics for COVID-19. The majority of these trials are designed to evaluate the comparative efficacy and safety of candidate therapeutics for the treatment of COVID-19 to prevent death among populations of hospitalized patients with advanced disease. Yet, emerging epidemiological evidence now indicates that the majority of those infected with the SARS-CoV-2, while still infectious, experience minimal or mild disease symptomology. Like HIV and hepatitis C that pioneered treatment as prevention, there is a missed opportunity for trials of early pharmaceutical intervention for COVID-19 disease evaluating not only reductions in morbidity and mortality but also transmissibility. We discuss this clinical research gap within an historical context of viral treatment as prevention for HIV and hepatitis C, and comment on the challenges and opportunities for clinical research of candidate therapeutics for early COVID-19 disease. äEarly Treatment of COVID-19 Disease: A Missed Opportunity (epmc).pdf DeepDyve Pubget Overpricing